American Heart Association - Scientific Sessions 2006. Developments in cardiovascular-related therapies.
Veryard
Claire
C
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. claire.veryard@thomson.com
D058908:Adenosine A2 Receptor Agonists; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D015949:Factor IXa / Q000037:antagonists & inhibitors; D015945:Factor XIa / Q000037:antagonists & inhibitors; D006801:Humans; D018078:Receptors, Prostaglandin E / Q000819:agonists; D058309:Receptors, Prostaglandin E, EP4 Subtype; D013203:Staphylococcal Infections / Q000517:prevention & control; D014640:Vancomycin / Q000008:administration & dosage; D014970:Xanthines / Q000627:therapeutic use
D058908:Adenosine A2 Receptor Agonists; D000893:Anti-Inflammatory Agents; C545650:PTGER4 protein, human; D018078:Receptors, Prostaglandin E; D058309:Receptors, Prostaglandin E, EP4 Subtype; D014970:Xanthines; D014640:Vancomycin; C073525:rolofylline; D015949:Factor IXa; D015945:Factor XIa